Eagle Pharmaceuticals Inc Receives a New Rating from Cantor Fitzgerald

By Jason Carr

In a report issued on June 11, Brandon Folkes from Cantor Fitzgerald initiated coverage with a Buy rating on Eagle Pharmaceuticals Inc (NASDAQ: EGRX) and a price target of $81. The company’s shares closed yesterday at $74.39.

According to TipRanks.com, Folkes is a 1-star analyst with an average return of 0.2% and a 55.0% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Collegium Pharmaceutical.

Eagle Pharmaceuticals Inc has an analyst consensus of Hold, with a price target consensus of $62.

See today’s analyst top recommended stocks >>

Eagle Pharmaceuticals Inc’s market cap is currently $1.1B and has a P/E ratio of 37.01. The company has a Price to Book ratio of 6.18.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban; ryanodex; docetaxel injection, non-alcohol formulation; and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.